IMMUNOME INC
NASDAQ: IMNM (Immunome, Inc.)
Last update: 52 minutes ago18.32
-0.10 (-0.54%)
| Previous Close | 18.42 |
| Open | 18.51 |
| Volume | 784,657 |
| Avg. Volume (3M) | 1,515,906 |
| Market Cap | 1,680,132,352 |
| Price / Sales | 150.97 |
| Price / Book | 6.40 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Operating Margin (TTM) | -1,525.50% |
| Diluted EPS (TTM) | -3.01 |
| Quarterly Revenue Growth (YOY) | 184.40% |
| Total Debt/Equity (MRQ) | 1.55% |
| Current Ratio (MRQ) | 10.49 |
| Operating Cash Flow (TTM) | -152.68 M |
| Levered Free Cash Flow (TTM) | -117.16 M |
| Return on Assets (TTM) | -33.54% |
| Return on Equity (TTM) | -69.21% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Immunome, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Average | 0.75 |
|
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 11.48% |
| % Held by Institutions | 83.28% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| T. Rowe Price Investment Management, Inc. | 30 Sep 2025 | 8,418,163 |
| Redmile Group, Llc | 30 Sep 2025 | 5,023,385 |
| Point72 Asset Management, L.P. | 30 Sep 2025 | 4,824,504 |
| Enavate Sciences Gp, Llc | 30 Sep 2025 | 4,768,583 |
| Ecor1 Capital, Llc | 30 Sep 2025 | 4,079,415 |
| Price T Rowe Associates Inc /Md/ | 30 Sep 2025 | 3,742,770 |
| Opaleye Management Inc. | 30 Sep 2025 | 3,185,000 |
| Primecap Management Co/Ca/ | 30 Sep 2025 | 3,018,009 |
| Jefferies Financial Group Inc. | 30 Sep 2025 | 2,100,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 36.00 (Truist Securities, 96.51%) | Buy |
| Median | 29.50 (61.03%) | |
| Low | 26.00 (Goldman Sachs, 41.92%) | Buy |
| 26.00 (Craig-Hallum, 41.92%) | Buy | |
| Average | 30.25 (65.12%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 14.19 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 01 Dec 2025 | 36.00 (96.51%) | Buy | 18.32 |
| Stephens & Co. | 17 Nov 2025 | 33.00 (80.13%) | Buy | 18.13 |
| Goldman Sachs | 22 Sep 2025 | 26.00 (41.92%) | Buy | 9.77 |
| Craig-Hallum | 05 Sep 2025 | 26.00 (41.92%) | Buy | 10.52 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 25 Nov 2025 | Announcement | Immunome to Present at Upcoming Investor Conferences |
| 06 Nov 2025 | Announcement | Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update |
| 04 Nov 2025 | Announcement | Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 31 Oct 2025 | Announcement | Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference |
| 23 Oct 2025 | Announcement | Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance |
| 02 Oct 2025 | Announcement | Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 18 Sep 2025 | Announcement | Infinimmune Announces Research Collaboration with Immunome |
| 04 Sep 2025 | Announcement | Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 03 Sep 2025 | Announcement | Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |